Daniel Bradbury
CIK 1236397 · CHAIRMAN · last filed 2026-07-28
Daniel Bradbury is a CHAIRMAN who has filed 276 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for VANI, was dated Jul 28, 2026. Across all open-market trades the lifetime net is −$176.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $20.7M across reported positions. 86 SEC filings were submitted jointly with ILLUMINA, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CSTL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2223 AVENIDA DE LA PLAYA, SUITE 108
LA JOLLA, CA 92037
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VANI | Director | — | $1.13 | — | $0 | 8 | 2026-07-28 |
| CSTL | Director | 35,631 | $33.30 | $1.19M | -$160.98M | 91 | 2026-06-01 |
| EQ | CHAIRMAN | 2,969,596 | $1.25 | $3.71M | $0 | 11 | 2026-05-29 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 39,471 | $19.00 | $749.9K | $500.0K | 9 | 2023-05-25 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 25,000 | $0.01 | $128 | $0 | 1 | 2021-02-26 |
| GERN | Director | 51,323 | $1.15 | $59.0K | $0 | 12 | 2019-04-01 |
| CORT | Director | 130,575 | $87.12 | $11.38M | -$480.2K | 16 | 2019-02-12 |
| ILMN | Director | 15,924 | $271.04 | $4.32M | -$14.97M | 79 | 2017-05-26 |
| BMR | Director | 4,139 | $1.31 | $5.4K | $0 | 1 | 2013-01-03 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | President & Chief Executive Of | 127,235 | — | — | -$574.8K | 30 | 2012-07-26 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | Director | 35,714 | — | — | $0 | 3 | 2008-02-15 |
Recent Filings
276 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-28 | VANI | Grant (A) | — | $0 | EDGAR |
| 2026-06-25 | VANI | Grant (A) | — | $0 | EDGAR |
| 2026-06-01 | CSTL | Grant (A) | — | $0 | EDGAR |
| 2026-05-29 | EQ | Grant (A) | — | $0 | EDGAR |
| 2026-05-27 | CSTL | Exer (M) | +13,667 | $0 | EDGAR |
| 2026-01-05 | VANI | Grant (A) | — | $0 | EDGAR |
| 2025-06-26 | VANI | Mixed | — | $0 | EDGAR |
| 2025-05-23 | CSTL | Mixed | +8,673 | $0 | EDGAR |
| 2025-02-19 | EQ | Mixed | — | $0 | EDGAR |
| 2025-02-07 | CSTL | Sell (S) | −7,867 | -$221.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.